Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy

Paul E Drawz, Lama Ghazi

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations

Abstract

The renin-angiotensin-aldosterone system (RAAS) plays a fundamental role in the physiology of blood pressure control and the pathophysiology of hypertension (HTN) with effects on vascular tone, sodium retention, oxidative stress, fibrosis, sympathetic tone, and inflammation. Fortunately, RAAS blocking agents have been available to treat HTN since the 1970s and newer medications are being developed. In this review, we will (1) examine new anti-hypertensive medications affecting the RAAS, (2) evaluate recent studies that help provide a better understanding of which patients may be more likely to benefit from RAAS blockade, and (3) review three recent pivotal randomized trials that involve newer RAAS blocking agents and inform clinical practice.

Original languageEnglish (US)
Article number297
JournalF1000Research
Volume6
DOIs
StatePublished - 2017

Bibliographical note

Publisher Copyright:
© 2017 Ghazi L and Drawz P.

Keywords

  • Anti-hypertensive drugs
  • Blocking agents
  • Blood pressure control
  • Hypertension
  • Renin-angiotensin-aldosterone system

Fingerprint Dive into the research topics of 'Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy'. Together they form a unique fingerprint.

Cite this